Physician profile
Gilbert Joseph Custer, JR.
NPI 1376554196
$4,372.65
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,950 · 2020: $840 · 2021: $1,433 · 2022: $150.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $840.52 | 2019-2021 | |
| Allergan, INC. | $434.03 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $410.88 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $317.66 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $275.94 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $261.67 | 2019-2021 | |
| Abbvie INC. | $254.14 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $219.84 | 2019-2021 | |
| Lundbeck LLC | $156.62 | 2019-2021 | |
| Shire North American Group INC | $155.67 | 2019 | |
| Adlon Therapeutics L.P. | $140.29 | 2019-2021 | |
| Neos Therapeutics, LP | $124.61 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $115.62 | 2019-2021 | |
| Eisai INC. | $105.00 | 2020-2021 | |
| Bausch Health US, LLC | $95.75 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $84.66 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $71.64 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $71.51 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $61.34 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $49.92 | 2019-2021 | |
| Alkermes, INC. | $41.62 | 2021-2022 | |
| Tris Pharma INC | $34.71 | 2019 | |
| Validus Pharmaceuticals LLC | $13.32 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.21 | 2019 | |
| Merck Sharp & Dohme LLC | $11.91 | 2019 | |
| Owp Pharmaceuticals, INC. | $11.57 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilbert Custer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.